A5064810176- Phagocytosis and Immune Regulation
- Pancreatic and Hepatic Oncology Research
- Pancreatitis Pathology and Treatment
- Hippo pathway signaling and YAP/TAZ
- PARP inhibition in cancer therapy
- Ubiquitin and proteasome pathways
- Cancer Immunotherapy and Biomarkers
- Cancer Mechanisms and Therapy
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Circular RNAs in diseases
- Cancer Research and Treatments
- Cancer-related gene regulation
- GDF15 and Related Biomarkers
- Bladder and Urothelial Cancer Treatments
- Cancer therapeutics and mechanisms
- Hepatocellular Carcinoma Treatment and Prognosis
- Cell death mechanisms and regulation
- Lung Cancer Research Studies
- Nutrition and Health in Aging
- Immunotherapy and Immune Responses
- Nutrition, Genetics, and Disease
- Chronic Lymphocytic Leukemia Research
- Neuroblastoma Research and Treatments
- Quinazolinone synthesis and applications
Kyoto Prefectural University of Medicine
1970-2024
Otsu Municipal Hospital
2019-2022
Combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapies (chemoimmunotherapy) is associated significantly better survival outcomes than alone in patients advanced non-small cell lung cancer (NSCLC). However, there are no prognostic markers for chemoimmunotherapy. The nutritional index (PNI) (LIPI) biomarkers inhibitor (ICI) monotherapy or chemotherapies. Thus, we aimed to examine whether these factors could also be We retrospectively examined 237 NSCLC treated In...
Anaplastic lymphoma kinase (ALK)-tyrosine inhibitors rarely elicit complete responses in patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC), as a small population of tumor cells survives due to adaptive resistance. Therefore, we focused on the mechanisms underlying resistance lorlatinib and therapeutic strategies required overcome them. We found that epidermal growth factor receptor (EGFR) signaling was involved NSCLC, activation which induced by heparin-binding...
We previously reported that combined therapy with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib and AXL ONO-7475 is effective in preventing the survival of drug-tolerant cells high-AXL-expressing EGFR-mutated non-small cell lung cancer (NSCLC) cells. Nevertheless, certain residual are anticipated to eventually develop acquired resistance this combination therapy. In study, we attempted establish a multidrug from first-line setting overcome NSCLC. siRNA...
Recently, novel Kirsten rat sarcoma viral oncogene homolog (KRAS) inhibitors have been clinically developed to treat KRAS G12C-mutated non-small cell lung cancer (NSCLC) patients. However, achieving complete tumor remission is challenging. Therefore, the optimal combined therapeutic intervention with G12C has a potentially crucial role in clinical outcomes of We investigated underlying molecular mechanisms adaptive resistance NSCLC cells devise strategy preventing drug-tolerant emergence....
<div>AbstractPurpose:<p>Rearranged during transfection (<i>RET</i>) aberrations represent a targetable oncogene in several tumor types, with RET inhibitors displaying marked efficacy. However, some patients RET-aberrant cancer are insensitive to tyrosine kinase (TKI). Recently, drug-tolerant mechanisms have attracted attention as targets for initial therapies overcome drug resistance. The underlying of cell emergence treated RET-TKIs derived from cells remain unknown....
<p>Supplementary Figure 1-11.</p>
Abstract Lazertinib, a novel third‐generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI), demonstrates marked efficacy in EGFR‐mutant lung cancer. However, resistance commonly develops, prompting consideration of therapeutic strategies to overcome initial drug mechanisms. This study aimed elucidate the adaptive lazertinib and advocate combination treatments that demonstrate preventing as first‐line treatment for EGFR mutation‐positive NSCLC. We found AXL knockdown...
Abstract Purpose: Rearranged during transfection (RET) aberrations represent a targetable oncogene in several tumor types, with RET inhibitors displaying marked efficacy. However, some patients RET-aberrant cancer are insensitive to tyrosine kinase (TKI). Recently, drug-tolerant mechanisms have attracted attention as targets for initial therapies overcome drug resistance. The underlying of cell emergence treated RET-TKIs derived from cells remain unknown. This study investigated the role...
Mycolicibacterium phlei (M. phlei) is known to be a non-pathogenic nontuberculous mycobacterium (NTM) which rarely causes diseases in humans. A disseminated NTM infection mostly caused by the Mycobacterium avium complex (MAC) and develop immunocompromised hosts, like those with acquired immune deficiency syndrome (AIDS). Here, we report case of M. an immunocompetent host carrying anti-interferon gamma (IFN-γ) autoantibodies. We detected multiple organs elderly woman no significant medical...
EGFR tyrosine kinase inhibitors are standard therapeutic agents for patients with advanced NSCLC harboring mutations. Nevertheless, some exhibit primary resistance to in the first-line treatment setting. AXL, a member of TYRO3, and MERTK family receptor kinases, is involved EGFR-mutated NSCLC.We investigated spatial tumor heterogeneity using autopsy specimens patient-derived cell line from patient having erlotinib plus ramucirumab.Quantitative polymerase chain reaction analysis revealed that...
Abstract Few treatment options exist for pleural mesothelioma (PM), which is a progressive malignant tumor. However, the efficacy of molecular-targeted monotherapy limited, and further therapeutic strategies are warranted to treat PM. Recently, cancer cell-cycle checkpoint inhibitors have attracted attention because they disrupt regulation. Here, we aimed establish novel combinational strategy inhibit kinase, ATR in PM cells. The siRNA screening assay showed that anexelekto (AXL) knockdown...
A 67-year-old man with primary lung adenocarcinoma was hospitalized due to massive bilateral pleural effusion and pericardial after 94 cycles of nivolumab therapy. We were unable identify the cause these effusions using blood tests, cytology or bacterial culture thoracoscopy. Finally, we administrated corticosteroids, which immediately improved fluid accumulation. This case may support introduction corticosteroids for late-onset during immune checkpoint inhibitor (ICI) treatment. However,...
Abstract Advanced granulocyte colony‐stimulating factor (G‐CSF)‐producing lung tumours are generally refractory to platinum‐based chemotherapy and associated with poor prognosis. However, therapeutic strategies for these remain unknown. A 74‐year‐old man was diagnosed non‐small cell cancer‐not otherwise specified (NSCLC‐NOS); the clinical stage T4N0M1c IVb. Blood testing showed leucocytosis aberrant G‐CSF expression. We chose single‐agent pembrolizumab as initial treatment because PD‐L1...